Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.
--------
Question: Paragraph: "The story had a sidebar explaining the cost of Bod Pod testing in Puget Sound locations ranges from $25 50. The story indicated one might benefit from the information generated by BOD POD measurement by helping set realistic weight loss goals. It did not actually provide the reader with any information about whether evidence exists demonstrating that it is of benefit for weight loss or improvement in adiposity-related risks. The story indicated that obtaining body composition information could be anxiety or guilt provoking. Although the story stated that 'Data suggest the BOD POD is accurate', it didn't actually indicate what sort of evidence exists documenting this. While theremay beevidence that the BOD POD is ""accurate"" the story did not state whether the evidence is solid or controversial. Most importantly, the story did not address the question as to whether there is any quality evidence that knowing your body fat percentage is truly helpful in improving your health. There also wasn't any evidence presented about how effective it is to measure body fat percentage prior to engaging in a weight loss program in terms of whether it helps people lose weight. The story did not engage in overt disease mongering. In fact, it concluded that having the test is ""not a good idea if the number will be just one more thing to obsess over or feel guilty about."" Both professionals interviewed were from the private commercial sector one from a center that uses the Bod Pod (hardly an independent voice on the topic) and one who is a book author. The story would have been enhanced with the inclusion of insight from a clear expert in the field of body composition assessment. The story did a very nice job of running through the various techniques for measuring body composition and even included a link to an online calculator of body mass index (BMI). The story explained that body composition measurement with the BOD POD is hard to find because there are few locations with the apparatus. The story accurately portrayed the BOD POD as a piece of equipment that had been around for a while. We can't be sure if the story relied largely or solely on a news release." Claim: What are you made of? The BOD POD knows all

Answer: This story did a fine job of explaining the various ways body composition can be measured and what the measurement means and how it might be used. But a major shortcoming of the story was that it did not do a good job of providing a critical appraisal of the evidence behind the BOD POD device. Do we really know that it is worthwhile to measure our body fat percentage? At what cost? If it is so beneficial, why doesn't my health care provider have a BOD POD in the office? What do clinicalexperts in body composition measurement say about the evidence that the BOD POD is a more useful tool than the body mass index? All unanswered, but important, questions for this story to address. This may be a case where our star ratings are deceptively high.

Question: Paragraph: House Speaker Jose Oliva was unsparing in his criticism of what he called the "healthcare industrial complex," including drug companies, hospitals and medical device companies that he said were "the great robber-barons of our time." Oliva sought to build on some of health care initiatives of last year's legislative session, including passage of a first-in-the-nation drug importation bill. "We did not choose healthcare as our priority," he said. "No, it chose us. It chose us through the sheer audacity of the defenders of the status quo." With a presidential election looming this fall, fierce partisan divides could influence the work of lawmakers. But an air of collegiality prevailed Tuesday, as bouquets festooned the chambers and the Capitol halls and rotundas pulsed with activity. Opening day was also important for lobbyists and the activists who seek to influence lawmakers and the legislation that will be crafted over the 60 days the Legislature has to complete its business before adjourning. While DeSantis enjoys strong relationships with lawmakers particularly his fellow Republicans who run both chambers of the statehouse he may not necessarily get everything he wants during his second year as the state's chief executive. His $91.4 billion budget calls for major spending on the environment and education including a nearly $1 billion outlay for teacher raises and bonuses. Some fiscally conservative lawmakers said they would give the spending intense scrutiny. On the eve of the Legislature's opening day, thousands of educators and their allies descended on the Capitol to draw attention to the governor's plan, calling it flawed because of potential pay inequities and because veteran educators and non-teaching school employees would be left out. Some key Republicans have also cast doubt on the governor's plan to require employers to use a federally operated electronic database known as E-Verify to check the immigration status of workers. E-Verify has been opposed by agriculture, construction, tourism interests and other industries that rely on immigrant labor. Hundreds of bills await, encompassing education spending, health care, the environment and public safety as well as approving the billions of dollars required to keep the country's third-most populous state operating day to day. Legislative Democrats are pushing for stronger gun control measures, but face long odds to win over their Republican colleagues. Addressing a joint session of the state House and Senate during his State of the State address, DeSantis urged cooperation particularly when it comes to approving his agenda on the environment and education. "This is Florida's season of opportunity," DeSantis told lawmakers. "We have the chance to build on a strong foundation, the chance to face the challenges before us and the chance to leave a legacy of success that will benefit our people now and in the future." Rep. Chris Sprowls, a Republican who's next in line to be House speaker, commended DeSantis for the sweep of his speech -- covering priorities, he said, that were crucial to Florida's future. "The members of the House want to help the governor because we believe in the same thing," Sprowls said. However, Sprowls declined to discuss the merits of specific legislation proposed by the governor, saying that task will be undertaken in the days and weeks to come. And while the governor's agenda appeared "bright," he said, "nothing is ever a slam dunk." In his opening remarks, Senate President Bill Galvano, a Republican, reminded lawmakers of their weighty responsibility. "As we go into this session let us continue to show our constituents that we can exchange and debate ideas while maintaining civility and decorum," he told the chamber. "That we can problem solve together. That we can put aside personalities and politics for good policy. And, that we are not a microcosm of Washington, D.C., but instead will continue to be an example for Washington, D.C." Claim: Florida Legislature sets sights on education, health care.

Answer: Florida lawmakers signaled that they would likely tackle education spending and health care costs but might seek to avoid a battle over forcing employers to verify the immigration status of workers, as the 2020 legislative session began Tuesday.

Question: Paragraph: The story goes into some detail about the cost of Folotyn, which is extraordinarily high. The story also does a great job of comparing the cost of the drug to other expensive cancer drugs. Costs were the main focus of the story. The story adequately quantitifes the benefits of Folotyn, which are not that impressive. The story provides the percentage of patients with reductions in tumor size and the median time that the benefits lasted. The story does not mention any potential harms of Folotyn. Although the primary focus of the story realtes to the drug's cost, it would have desriable to provide a brief comment on the toxicity of the drug as well. The addition of the information would help the reader place the value of the drug into a better perspective. According to the package insert, 44% of patients treated in the clinical trial suffered from a serious side effect of the drug The storydescribes the evidence tosupport Folotyn, which is rather thin. The story mentions one clinical trial that showed a reduction in tumor size in some participants, but that to date, the drug has not been shown toprolong longevity. The quote from a member of the FDA advisory board that recommended approval provides an excellent overview and counterpoint to the comments of the company spokesperson. The story accurately represents the seriousness and prevalence of peripheral T-cell Lymphoma, which is quite rare and serious. The story quotes multiple stakeholders, including experts from the drug manufacturer, a largeinsurance company, and lymphoma researchers. The provide valuable diversity of perspectives on this controversial issue. The story clearly states that there are no alternatives to Folotyn for this particular indications, but compares the price of the drug to several other expensive cancer drugs. The story should have emphasized that Folotyn was studied in patients who have relapsed and a comparison with currently used regimens is not available. The story clearly states that Folotyn is not currently available but that the manufacturer plans to market the drug in January. The story clearly states that Folotyn is new. It could have stated that a host of older and less expensive treatment options are currently available. Because the story quotes mutliple experts, the reader can assume the story did not rely on a press release as the sole source of information. Claim: Questioning a $30,000-a-Month Cancer Drug

Answer:
This story focuses on issue of the cost of a new cancer drug, but it also provides valuable and balanced information for the reader on the drug, Fotolyn, in terms of its potential benefits, availability, novelty, andevidence to support its use. Notably, the story quotes multiple stakeholders, including experts from the drug manufacturer, a largeinsurance company, and lymphoma researchers. These quotesprovide diversity of perspectives on this controversial issue. Recent debates on health care reform in the United States have highlighted the complex problem of cost of drugs and treatments. Healthcare costs are rising at alarming rates, causing a significant drag on our economy. How much is too much to spend on a new drug? The recent news of the FDA approval of Folotyn, a chemotherapy drug for peripheral T-cell lymphoma, a rare and serious cancer, has raised this question in dramatic fashion. Folotyn is projected to cost $30,000 per month, quite a bit higher than other high priced cancer drugs. Folotyn is projected to be a money-maker for the manufacturer, Allos Therapeutics.